Abstract: The invention relates to retinal disorders, and to genetic constructs and recombinant vectors comprising such constructs, and their use in gene therapy methods for treating, preventing or ameliorating a wide range of retinal disorders. The constructs and vectors are particularly useful for treating wet age-related macular degeneration (wet-AMD), i.e., neovascular age related macular degeneration. The invention extends to the use of the constructs and vectors for reducing vascular leakage and retinal cell damage. The invention also extends to pharmaceutical compositions per se, and their use in treating, preventing or ameliorating retinal disorders, and for reducing vascular leakage and retinal cell damage.

Abstract: The invention relates to retinal disorders, and to genetic constructs and recombinant vectors comprising such constructs, and their use in gene therapy methods for treating, preventing or ameliorating a wide range of retinal disorders. The constructs and vectors are particularly useful for treating geographic atrophy (GA) and dry age-related macular degeneration (dry-AMD). The invention extends to the use of the constructs and vectors for reducing complement activation and retinal cell damage and loss. The invention also extends to pharmaceutical compositions per se, and their use in treating, preventing or ameliorating retinal disorders, and reducing complement activation and retinal cell damage and loss.

Abstract: The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for treating a range of disorders, including glaucoma and deafness, or for promoting nerve regeneration and/or survival.

Abstract: The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for the treatment, prevention or amelioration of a neurodegenerative disorder, including Alzheimer's disease, Parkinson's disease, Huntington's disease, motor neurone disease, or for the treatment of stroke, or for promoting nerve regeneration and/or survival.

Abstract: The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for treating a range of disorders, including glaucoma and deafness, or for promoting nerve regeneration and/or survival.

Abstract: The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for treating a range of disorders, including glaucoma and deafness, or for promoting nerve regeneration and/or survival.

Abstract: The invention provides genetic constructs and recombinant vectors comprising such constructs. The constructs and vectors can be used in gene therapy methods for treating a range of disorders, including glaucoma and deafness, or for promoting nerve regeneration and/or survival.

Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.

Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.

Abstract: Provided is a lentiviral vector for delivery to the brain for use in treating a neurological condition, wherein the lentiviral vector is delivered directly to the brain by delivering the lentiviral vector via six or fewer tracts per hemisphere, at a single deposit point per tract.

Abstract: The present invention is directed to therapeutic compounds which have dual activity as agonists of GPR119 and inhibitors of DPP-IV and are useful for the treatment of metabolic disorders including type II diabetes.

Abstract: The present invention is directed to the use of G-protein coupled receptor agonists for the treatment of beta-cell degeneration.